Noticias de AUPH_US

Noticias del mercado

Últimas noticias sobre AUPH_US — 160 novedades recientes. Análisis, balances, opiniones y cobertura de prensa.

Ticker: AUPH_US ✕ 160 resultados
13/05/2026 AUPH_US — AD HOC NEWS
Aurinia Pharmaceuticals stock (CA05156H1070): Announces $6.955 Cash Acquisition of Kezar Life Scienc

Aurinia Pharmaceuticals has agreed to acquire Kezar Life Sciences for $6.955 per share in cash, expa

12/05/2026 AUPH_US — TradingKey
TradingKey
11/05/2026 AUPH_US — Stock Titan
Morgan Stanley Smith Barney to sell 3.14M AUPH shares (AUPH) on 05/11/2026
11/05/2026 AUPH_US — Stock Titan
AUPH (NASDAQ: AUPH) Proposed sale of 717,688 common shares
11/05/2026 AUPH_US — Stock Titan
500,503 AUPH shares listed for resale by Morgan Stanley (NASDAQ: AUPH)
11/05/2026 AUPH_US — Investing.com ES ← EN
Aurinia Pharmaceuticals completa la adquisición de Kezar Life Sciences

Aurinia Pharmaceuticals completes acquisition of Kezar Life Sciences

11/05/2026 AUPH_US — Investing.com ES ← EN
Aurinia Pharmaceuticals completa la adquisición de Kezar Life Sciences Por Investing.com

Aurinia Pharmaceuticals completes acquisition of Kezar Life Sciences By Investing.com

11/05/2026 AUPH_US — Investing.com ES ← EN
Aurinia Pharmaceuticals completa la adquisición de Kezar Life Sciences

Aurinia Pharmaceuticals completes acquisition of Kezar Life Sciences

11/05/2026 AUPH_US — Investing.com
Aurinia Pharmaceuticals completes acquisition of Kezar Life Sciences
11/05/2026 AUPH_US — Investing.com ES ← EN
Aurinia Pharmaceuticals completa la adquisición de Kezar Life Sciences Por Investing.com

Aurinia Pharmaceuticals completes acquisition of Kezar Life Sciences By Investing.com

11/05/2026 AUPH_US — Stock Titan
Aurinia acquires Kezar Life Sciences (NASDAQ: KZR) in cash-and-CVR deal
11/05/2026 AUPH_US — Stock Titan
Aurinia Pharmaceuticals (NASDAQ: AUPH) closes Kezar Life Sciences cash-and-CVR deal
11/05/2026 AUPH_US — Stock Titan
Aurinia (KZR) completes merger with Kezar — $6.955 per share plus CVR
11/05/2026 AUPH_US — Stock Titan
Aurinia to acquire Kezar Life Sciences (NASDAQ: KZR) in cash and CVR deal
11/05/2026 AUPH_US — Sahm
A Look At Aurinia Pharmaceuticals (AUPH) Valuation After Strong Q1 2026 Earnings Beat
10/05/2026 AUPH_US — AD HOC NEWS
Aurinia Pharmaceuticals stock (CA05156H1070): Lupus drug developer eyes broader kidney disease marke

Aurinia Pharmaceuticals continúa ampliando su presencia en enfermedades renales autoinmunes, con su lu

09/05/2026 AUPH_US — news.futunn.com
Aurinia Pharmaceuticals Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
09/05/2026 AUPH_US — Yahoo Finance
Aurinia Pharmaceuticals Inc. Just Beat EPS By 28%: Here's What Analysts Think Will Happen Next

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) informó la semana pasada sus últimos resultados trimestrales, lo que lo convierte en un buen...

09/05/2026 AUPH_US — Yahoo Finance ES ← EN
Aurinia Pharmaceuticals Inc. acaba de superar las ganancias por acción en un 28%: esto es lo que los analistas creen que sucederá a continuación

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) informó la semana pasada sus últimos resultados trimestrales, lo que lo convierte en un buen...

08/05/2026 AUPH_US — Sahm
Aurinia Pharmaceuticals (AUPH) Is Up 6.3% After Stronger Q1 LUPKYNIS-Driven Profitability Has The Bull Case Changed?

Página 1 de 8

keyboard_arrow_up